Open this publication in new window or tab >>Show others...
2022 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 56, no 3, p. 169-175Article in journal (Refereed) Published
Abstract [en]
Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in men with non-metastatic castration sensitive prostate cancer (nmCSPC).
Materials and Methods: PSA values for 1603 men with nmCSPC in the National Prostate Cancer Register of Sweden who received GnRH as primary treatment were retrieved from Uppsala-Örebro PSA Cohort and Stockholm PSA and Biopsy Register. All men had measured PSA before (pre-GnRH PSA) and 3–6 months after (post-GnRH PSA) date of start of GnRH. Unadjusted and adjusted Cox models were used to predict CRPC by PSA levels. PSA levels and ISUP grade were used to construct a risk score to stratify men by tertiles according to risk of CRPC and Pca death.
Results: 788 (49%) men reached CRPC and 456 (28%) died of Pca during follow-up. Post-GnRH PSA predicted CRPC regardless of pre-GnRH PSA. CRPC risk increased with higher post-GnRH PSA, HR 4.7 (95% CI: 3.4–6.7) for PSA > 16 ng/mL vs 0–0.25 ng/mL and with ISUP grade, HR 3.7 (95%: 2.5–5.4) for ISUP 5 vs ISUP 1. Risk of Pca death in men above top vs bellow bottom tertile of post-GnRH PSA and ISUP grade was HR 4.1 (95% CI: 3.0–5.5).
Conclusion: A risk score based on post-GnRH PSA and ISUP grade could be used for early identification of a target group for future clinical trials on additional therapy to GnRH.
Place, publisher, year, edition, pages
Taylor & Francis, 2022
Keywords
Prostatic neoplasms; prostatic neoplasms; castration-resistant; neo-plasm grading; prostate-specific antigen; gonadotropin-releasing hormone; prognosis; mortality
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-217075 (URN)10.1080/21681805.2022.2070275 (DOI)000794215300001 ()35548951 (PubMedID)2-s2.0-85130235285 (Scopus ID)
Note
Funding: This project received research support from the Swedish Cancer Society, the Swedish Research Council, the Clinical Cancer Research Foundation in Jönköping, Sweden [FUTURUM-964541] and from FUTURUM - Academy for Healthcare, Jönköping County, Sweden.
2025-08-292025-08-292025-08-29Bibliographically approved